Sign in
Taking people in United StatesPhase 2

Testing Breathing Support and Oxygen During Sleep in Sleep Apnea With COPD

Compares nighttime breathing machine and oxygen therapy in adults with sleep apnea and COPD.

Key facts

Who runs it
University of California, San Diego
Where
La Jolla, United StatesSee the site
Trial code
Registry title
The Cardiovascular Consequences of Sleep Apnea Plus COPD (Overlap Syndrome)
Status
Recruiting
Phase
Phase 2
People taking part
240 people, planned
Started
13 Feb 2024
Expected to end
31 Aug 2028
Type of study
Interventional, 2 groups
Treatments tested
  • bi-level positive pressure non invasive ventilation
  • Oxygen gas
Record updated
3 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 40-79 with untreated moderate to severe obstructive sleep apnea and/or COPD. Women must be past menopause.

Age
40 to 79 years
Sex
All sexes. Women must be postmenopausal.
Disease stage
Untreated moderate to severe obstructive sleep apnea (apnea-hypopnea index 15 to 80 events per hour) and/or COPD (FEV1/FVC ratio below 0.7) on stable medications.
Earlier treatment
People already on continuous oxygen for COPD or on PAP treatment for sleep apnea cannot join. Medications must be stable.
Biomarker or test result
Apnea-hypopnea index of 15 to 80 events per hour for sleep apnea. FEV1/FVC ratio below 0.7 for COPD.

Main reasons for not taking part

  • Premenopausal women, pregnant women or women who are breastfeeding
  • Pacemakers, defibrillators or other implanted devices or metal in the body
  • Central sleep apnea, Cheyne-Stokes breathing or other severe sleep disorders
  • Lung disease other than COPD, or active cancer treatment
  • Oxygen level that stays below 89% while awake

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Persons aged 40-79
  • For women, only postmenopausal women will be included
  • Diagnosed with untreated moderate to severe obstructive sleep apnea (apnea-hypopnea index ≥15 events/hr and ≤80 events/hr) and/or diagnosed with COPD with FEV1/FVC ratio <0.7 and will be on stable medications as assessed by a board-certified pulmonologist

Who cannot take part

  • Concurrent severe sleep disorders (such as periodic limb movements, restless legs syndrome, narcolepsy, idiopathic hypersomnia, etc)
  • Take potentially confounding medications or hormones that affect breathing
  • people with exposures deemed to be problematic for the research e.g. any smoking in bedroom by participant or household member, major second-hand smoke, e-cigarettes, tetrahydrocannabinol, major drug or alcohol consumption (>3 oz/day) and other environmental pollution effects (indoor and outdoor)
  • Presence of specific devices: cardiac implantable electronic device (CIED) such as pacemakers, implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy (CRT) devices, metallic foreign bodies, implantable neurostimulation systems, cochlear implants/ear implant, drug infusion pumps (insulin delivery, analgesic drugs, or chemotherapy pumps), metallic fragments such as bullets, shotgun pellets, and metal shrapnel , cerebral artery aneurysm clips, magnetic dental implants, and artificial limb
  • Known allergic reactions to components of the study intervention: (if getting contrast, MRI contrast (gadolinium))
  • Subjects will be excluded if they are deemed medically unstable with active neurological, cardiac, liver, endocrine, and infectious diseases
  • We will also exclude participants with pulmonary disease apart from COPD
  • We will exclude participants with active cancer treatment
  • Individuals with OSA (AHI range 15-80/hr) will be screened for pathological sleepiness and will be excluded if ESS >18/24, history of motor vehicle accident or near miss accident, or high-risk occupation
  • Premenopausal women (i.e. women are pregnant or may become pregnant) or lactation
  • Exhibit Cheyne-Stokes respiration or central sleep apnea (> 25 % of events central)
  • We will exclude azotemia (estimated glomerular fraction rate < 30ml/min) as there is some concern about giving gadolinium to these patients (if getting contrast MRI)
  • Individuals who are already on continuous O2 for COPD or PAP treatment for OSA
  • Patients with sustained desaturations below 89% during wake time will be excluded for ethical reasons since withholding oxygen in hypoxemic patients would be at odds with standard of care
  • COPD individuals with arterial PCO2 higher than 52 mmHg will be excluded
  • Individuals who are currently incarcerated

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 40 and 79 years old?

Where in United States

  • UCSD Sleep ResearchLa Jolla, United StatesContact: Pam DeYoung, RPSGTTaking people

About the trial

What the trial wants to find out

Major progress has been made in the area of cardiovascular disease, but we believe that further progress will involve mechanistically addressing underlying respiratory causes including chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea (OSA). The most common cause of death in COPD is cardiovascular, although mechanisms are unknown. OSA has been associated with major neurocognitive and cardiovascular sequelae, the latter likely a function of autonomic nervous system abnormalities, oxidative stress, inflammation, and other pathways. Recent data suggest that individuals with OVS die preferentially of cardiovascular disease compared to OSA or COPD alone, although mechanisms are again unclear.

Read full original descriptionShow less

The combination of OSA and COPD may lead to profound hypoxemia. Individuals with COPD can develop pulmonary hypertension via disturbances in gas exchange and parenchymal injury leading to loss of pulmonary vasculature. OSA has been associated with mild to moderate pulmonary hypertension, but the situation may be worse if combined with parenchymal lung disease. The biological response to sustained hypoxemia has been carefully studied as has the topic of intermittent hypoxemia; however, to our knowledge, very little research has occurred regarding the combination of sustained plus intermittent hypoxia as seen in OVS. For example, we do not really know whether individuals with OVS develop coronary disease, right or left heart failure, dysrhythmias or some combination of abnormalities predisposing them to cardiovascular death. Thus, design of interventional studies is challenging as causal pathways are poorly understood despite our considerable preliminary data addressing these issues.

The purpose of this study is to examine vascular mechanisms in individuals with COPD/OSA overlap syndrome (OVS) compared with matched individuals with obstructive sleep apnea (OSA) alone or chronic obstructive pulmonary disease (COPD) alone and to perform a phase II pilot mechanistic clinical trial in OVS to examine the effect size of nocturnal bi-level positive airway pressure (PAP) vs. nocturnal oxygen therapy in cardiovascular outcomes.

The 2 groups in the trial

  • OxygenTreatment being tested

    OVS subjects will receive treatment with oxygen during night time for 6 months

    Treatment: Oxygen gas

  • Bi-level positive pressure non invasive ventilationTreatment being tested

    OVS subjects will receive treatment with bi-level PAP therapy during night time for 6 months

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Cardiovascular Consequences of Sleep Apnea Plus COPD (Overlap Syndrome)
Plain-language title
Testing Breathing Support and Oxygen During Sleep in Sleep Apnea With COPDGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Criteria questions
Built from NCT05237505, who can take part
Record updated
3 June 2026